glp-1 layoffs news medications could cut US mortality by 6.4%, new study finds Your Weight-Loss Drugs Are Next
Description
Currently available FDA-approved GLP-1 RAs include several monotherapy agents and one combination multi-agonist, the dual GLP-1/GIP agonist tirzepatide (Zheng et al., 2024)
And what I'm teaching in that course is what I teach clinicians and I train clinicians
Available as Saxenda for weight loss and Victoza for diabetes, it requires daily injections rather than weekly ones
The observed protective effects are mediated through multiple molecular mechanisms, including enhanced metabolic regulation, direct anti-proliferative actions, and augmented immune surveillance [16, 17]
